Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens

AIDS

Volumn 26, Issue 14, 2012, Pages 1837-1840

  Bigoloni, Alba ^a   Gianotti, Nicola ^a   Spagnuolo, Vincenzo ^a   Galli, Laura ^a   Nozza, Silvia ^a   Cossarini, Francesca ^a   Salpietro, Stefania ^a   Carini, Elisabetta ^a   Piatti, Piermarco ^c   Vinci, Concetta ^a   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Metabolic and Cardiovascular Division   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; GLUCOSE; INSULIN; MARAVIROC; RALTEGRAVIR;

ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LETTER; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BLOOD GLUCOSE; CYCLOHEXANES; FASTING; GLUCOSE TOLERANCE TEST; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INSULIN; INSULIN RESISTANCE; PYRIDAZINES; PYRROLIDINONES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 84866329563     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835705dd     Document Type: Letter

References (17)

1. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739-1745. (Pubitemid 47237561)
2. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
3. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227-1234.
4. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12:149-162. (Pubitemid 46569900)
5. HIV/AIDS Italian Expert Panel. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 [Italian guidelines on the use of antiretroviral drugs and on the clinical and diagnostic management of persons living with HIV-1]. 2011. http://www.salute.gov.it/hiv/hiv.jsp. [Accessed 29 December 2011]
6. The EACS Executive Committee. The European AIDS Clinical Society (EACS) guidelines. Version 6.0. 2011. http://www.euro peanaidsclinicalsociety.org/. [Accessed 29 December 2011]
7. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119. (Pubitemid 46984626)
8. Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, Liu WC, et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med 2009; 10:302-309.
9. Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17:1993-1995. (Pubitemid 37070289)
10. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26:303-314.
11. Grunfeld C. Understanding the complications of antiretroviral drugs. Clin Infect Dis 2008; 47:575-576.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
13. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005; 107:44-58. (Pubitemid 40803508)
14. Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, et al. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 2008; 128:57-65.
15. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85: 289-291.
16. Moldawer LL, Sattler FR. Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation. Semin Oncol 1998; 25:73-81. (Pubitemid 28093158)
17. Andersson J, Fehniger TE, Patterson BK, Pottage J, Agnoli M, Jones P, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12: F123-F129. (Pubitemid 28330715)